Gonzalez MC, Ashton NJ, Gomes BF, et al. - Findings imply that plasma phosphorylated tau (p-tau) (p-tau181 and p-tau231) concentrations could be employed as cost-effective as well as accessible biomarkers to evaluate cognitive decline in persons with dementia with Lewy bodies (DLB).

• This is a cohort study of 987 participants from the European-DLB Consortium; clinically diagnosed individuals with probable DLB (n = 371), Parkinson disease (n = 204), Alzheimer disease (AD) (n = 207), as well as healthy controls (n = 205).

• In participants with DLB, plasma p-tau181 and p-tau23 concentrations were significantly higher compared with those in healthy controls and lower relative to those in patients with AD.

• Concentrations of plasma p-tau181 and p-tau231 were identified to be related to cognitive impairment at baseline and more rapid cognitive decline during follow-up post-adjustment for gender and age.